Rampart Bioscience raises $125M for non-viral gene therapies

Ryan Cross

Senior Science Correspondent

A new California biotech startup has launched with plans to develop genetic medicines that are durable, redoseable, and perhaps most importantly, don’t overwhelm health budgets.

Rampart Bioscience said Tuesday morning it has raised $125 million, including a $40 million seed investment from OrbiMed, as well as an $85 million Series A financing led by Forbion, with OrbiMed, RA Capital Management and HealthCap participating in the round.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Rampart Bioscience raises $125M for non-viral gene therapies

Ryan Cross

Senior Science Correspondent

Unlock this article instantly by becoming a free subscriber.

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Marinus lays off 20% of workforce, cuts costs to stay afloat

Medical Affairs: The Critical Link Between Science, Physicians and Patients

Ram­part Bio­science rais­es $125M for non-vi­ral gene ther­a­pies

Ryan Cross

Senior Science Correspondent

Unlock this article instantly by becoming a free subscriber.

Af­ter eight years with Sanofi, Frank Nes­tle de­parts as CSO, glob­al head of re­search

Pa­tient dies in Pfiz­er’s Phase 2 Duchenne mus­cu­lar dy­s­tro­phy tri­al

'Big­ger, faster, bet­ter': Iso­mor­phic, Deep­Mind un­veil Al­phaFold 3, go­ing be­yond pro­tein pre­dic­tions

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

Mar­i­nus lays off 20% of work­force, cuts costs to stay afloat

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

Rampart Bioscience raises $125M for non-viral gene therapies

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Marinus lays off 20% of workforce, cuts costs to stay afloat

Medical Affairs: The Critical Link Between Science, Physicians and Patients